CPI-0209-01 (Constellation)
Description: A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors
Target Patient Population: In Phase 2 with slots for tumors with known ARID1A mutations in Lymphoma, Mesothelioma, Urothelial and Endometrial.
Study Design: Drug is given orally daily.